MIU
ACOR

Man Investments (UK)’s Acorda Therapeutics ACOR Stock Holding History

Man Investments (UK)’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-291
Closed -$1.2M – 701
2013
Q3 		$1.2M Buy
+291
New +$1.25M 0.16% 270

Other funds holding ACOR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Man Investments (UK)'s ACOR Position: Q4 2013 in Review

Man Investments (UK) sold out of Acorda Therapeutics (ACOR) in Q4 2013, closing a stake of 291 shares — an estimated $1.2M sold.

Man Investments (UK) first reported a position in ACOR in Q3 2013 and held it in 1 quarter. The position peaked at $1.2M in Q3 2013. 163 funds tracked by Wall St. Rank hold ACOR as of Q4 2013.

  • Man Investments (UK) reported no remaining Acorda Therapeutics position as of Q4 2013 after selling out during the quarter.
  • Man Investments (UK) sold 291 Acorda Therapeutics shares in Q4 2013, an estimated $1.2M.
  • Man Investments (UK) first reported a position in Acorda Therapeutics in Q3 2013 and held it in 1 quarter.
  • Man Investments (UK)'s Acorda Therapeutics position peaked at $1.2M in Q3 2013.
  • 163 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q4 2013.

Based on Man Investments (UK)'s 13F filing for Q4 2013, filed 14 Feb 2014.